PPARγ agonists have demonstrated efficacy in a range of animal models for CNS inflammatory and neurodegenerative disorders, including AD [72], PD [73,74], HD [75], ALS, and Friedreich’s ataxia (FRDA) [76]. This evidence concerns the gene PPARG and Parkinson disease.